Exploring how tobacco toxins interact with genes related to heart disease.
Identifying tobacco-genetic interactions through study of the aryl hydrocarbon receptor pathway.
This study is looking at how harmful substances in tobacco might affect heart health by exploring how they interact with certain genes, which could help us find better ways to prevent and treat coronary artery disease for people who smoke or are exposed to tobacco.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10812396 on NIH RePORTER |
What this research studies
This research investigates the relationship between environmental toxins found in tobacco products and their impact on coronary artery disease (CAD) by focusing on specific genes involved in this process. Using a reverse genetics approach, the study aims to identify how these toxins interact with the aryl hydrocarbon receptor (AHR) and other related genes. By analyzing genetic and molecular mechanisms, the research seeks to uncover the pathways through which tobacco exposure increases CAD risk, potentially leading to new insights into prevention and treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with a history of tobacco use and those at risk for coronary artery disease.
Not a fit: Patients who do not use tobacco and have no risk factors for coronary artery disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and prevention strategies for coronary artery disease linked to tobacco exposure.
How similar studies have performed: Previous research has shown success in identifying gene-environment interactions related to cardiovascular diseases, suggesting that this approach may yield valuable insights.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Quertermous, Thomas — Stanford University
- Study coordinator: Quertermous, Thomas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.